drugset / Trial / NCT05169515
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL.
Timeline
- Start
- 2022-10-26
- Primary completion
- 2029-09-15
- Completion
- 2029-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glofitamab | Monoclonal antibody | — | Intravenous |
| Subject | Golcadomide | Other / unclassified | — | Oral |
| Subject | Iberdomide | Small molecule | — | Oral |
| Subject | Mosunetuzumab | Monoclonal antibody | — | Subcutaneous |
| Background | Obinutuzumab | Monoclonal antibody | — | Intravenous |
| Background | Tocilizumab | Monoclonal antibody | — | Intravenous |